摘要
非小细胞肺癌(NSCLC)患者的治疗方式多样,除放疗、化疗、靶向治疗外,免疫检查点抑制剂也取得突破性进展,尤其是程序性细胞死亡受体-1(PD-1)及其配体(PD-L1)抑制剂改善了NSCLC患者的生存,部分被美国食品和药物管理局批准为一线用药。目前常用的PD-L1抑制剂有阿特珠单抗、度伐利尤单抗和阿维鲁单抗,联合疗法包括联合化疗、血管内皮生长因子抑制剂、分子靶向治疗和免疫治疗。
Patients with non-small cell lung cancer(NSCLC)are treated in a variety of ways.In addition to radiotherapy,chemotherapy and targeted therapy,breakthroughs have been made in immune checkpoint inhibitors,in particular,programmed cell death 1(PD-1)and its ligand(PD-L1)inhibitors have achieved survival benefits for NSCLC patients,and some of them have been approved as first-line drugs by the US Food and Drug Administration.Currently,commonly used PD-L1 inhibitors are atezolizumab,durvalumab and avelumab.Combination therapies include combination with chemotherapy,anti-vascular endothelial growth factor drugs,molecular targeted therapy and immunotherapy.
作者
谢红霞
左金辉
廖冬颖
邓仁芬
姚杨
贾英杰
李小江
孔凡铭
Xie Hongxia;Zuo Jinhui;Liao Dongying;Deng Renfen;Yao Yang;Jia Yingjie;Li Xiaojiang;Kong Fanming(Department of Oncology,First Teaching Hospital of Tianjin University of Traditional Chinese Medicine National Clinical Research Center for Chinese Medicine Acupuncture and Moxibustion,Tianjin 300382,China)
出处
《国际肿瘤学杂志》
CAS
2022年第2期111-115,共5页
Journal of International Oncology
